Circle
Get the Wire

Core Scientific, Inc. – Securities Disclosure Risk Research Review

Date:

Category:

Alert

Author:

Summary:

Core Scientific, Inc. has restated its 2024 and 2025 financial statements after disclosing accounting errors related to the improper capitalization of assets during facility conversions. The audit also identified material weaknesses in internal controls, raising securities disclosure risks and potential impacts on investor confidence as the company restructures its business model.

Related Articles

TruGolf Capital Structure & Disclosure Practices

Read More

Super Micro Computer, Inc. – Securities Disclosure Risk Research Review

Read More

DoorDash Pricing & Fee Transparency

Read More

AI Revenue Representation Investigation

Read More

Biotech Capital Formation and Disclosure Investigation

Read More

Consumer Fintech Pricing Practices Investigation

Read More

Related Articles

TruGolf Capital Structure & Disclosure Practices

Read More

Super Micro Computer, Inc. – Securities Disclosure Risk Research Review

Read More

DoorDash Pricing & Fee Transparency

Read More

AI Revenue Representation Investigation

Read More

Biotech Capital Formation and Disclosure Investigation

Read More

Consumer Fintech Pricing Practices Investigation

Read More

Core Scientific, Inc. – Securities Disclosure Risk Research Review

Core Scientific, Inc. has restated its 2024 and 2025 financial statements after disclosing accounting errors related to the improper capitalization of assets during facility conversions. The audit also identified material weaknesses in internal controls, raising securities disclosure risks and potential impacts on inve
Status: Development
Last Updated: June 16, 2026
Press Release
Explanatory Video
Vigilant Risk Score

86

Escalation Momentum Score

78

Litigation Readiness Index

82

Legal Process Indicator LPI

60

60
Legal Process Indicator LSB

Loss Severity Band

$50-250m
Threat Horizon IndexTHI

6-18mo

6-18mo
Case Impact ScoreCIS

70

70

company & product

  • Industry: High-Performance Computing and Digital Asset Mining
  • Public / Private: Public
  • Headquarters: Dover, Delaware
  • Market Cap: Approximately $8.93 billion
  • Core Products/Services: High-performance computing colocation services, digital asset mining
  • Who is Exposed: Investors, shareholders, regulatory bodies

Executive Intelligence summary

Core Scientific, Inc. has restated its 2024 and 2025 financial statements after disclosing accounting errors related to the improper capitalization of assets during facility conversions. The audit also identified material weaknesses in internal controls, raising securities disclosure risks and potential impacts on investor confidence as the company restructures its business model.

issues under review

Issue 1

  • What is observable: Restatement of financial statements for 2024 and 2025 due to improper capitalization of assets committed to demolition during facility conversions.
  • Why it matters: Restatements can affect financial transparency and investor trust.
  • What triggered it: Identification of accounting errors during the preparation of the 2025 financial statements.

Issue 2

  • What is observable: Identification of a material weakness in internal control over financial reporting.
  • Why it matters: Material weaknesses indicate potential for misstatements in financial reporting.
  • What triggered it: Errors in accounting for assets during facility conversions.

Issue 3

  • What is observable: Declining year-over-year revenue as the company shifts its business mix.
  • Why it matters: Revenue declines can complicate investor modeling and valuation.
  • What triggered it: Transition from digital asset mining to high-performance computing colocation services.

Research Status & Methodology

This research is based on publicly available information, including SEC filings and company press releases, with a focus on identifying and structuring risk signals related to securities disclosure.

Potential legal Exposure

The combination of financial restatements, internal control weaknesses, and a shifting business model may pose moderate securities disclosure risks, potentially affecting investor confidence and increasing the risk of regulatory scrutiny.

Potential defendants

  • Core Scientific, Inc.

Research status & Methodology

This research is based on publicly available information, including SEC filings and company press releases, with a focus on identifying and structuring risk signals related to securities disclosure.

EVIDENCE AND SOURCE LINKS

https://investors.corescientific.com/sec-filings/all-sec-filings/content/0001628280-26-013214/core-20260302.htm?utm_source=openai

SEC Filing – Restatement of 2024 and 2025 financial statements (March 2, 2026)

https://investors.corescientific.com/sec-filings/all-sec-filings/content/0001628280-26-013214/core-20260302.htm?utm_source=openai

SEC Filing – Material weakness in internal control (March 2, 2026)

https://investors.corescientific.com/sec-filings/all-sec-filings/content/0001628280-26-031246/core-20260506.htm?utm_source=openai

SEC Filing – Declining revenue and shift in business mix (May 6, 2026)

VIEW All SOURCES

Contribute Information

Receive Research Updates
Join Monitoring List
Submit Information
Restatements and material control weaknesses, especially following a business model shift, may expose investors to historical misstatement risk and create a fact pattern attractive to securities class action counsel. The non‑reliance language and adverse opinion could support arguments that prior disclosures were materially incomplete or misleading.

Search company, ticker, executive, director or issue

Receive Research Updates













    Join Monitoring List





      Submit Information